Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20413287 | 0.95 | KDM4E (0.42) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL20413281 | 0.94 | NPC1 (0.40) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL15470210 | 0.90 | TLR8 (0.47) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL20413282 | 0.88 | KDM4E (0.41) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL20219493 | 0.88 | SMN1; SMN2 (0.40) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL15470199 | 0.85 | TLR8 (0.44) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL15470181 | 0.84 | KCNH2 (0.48) | KDM4ENPC1RAB9ASMN1; SMN2TLR8 | |
| SCHEMBL23472299 | 0.84 | NPC1 (0.44) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL20219589 | 0.84 | SMN1; SMN2 (0.40) | KDM4ENPC1RAB9AMAPTLMNA | |
| SCHEMBL23472680 | 0.82 | KDM4E (0.40) | KDM4ENPC1RAB9AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | KDM4E 1994/4885NPC1 1081/4885RAB9A 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.